Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-916 in early Alzheimer's disease
NCT05291234Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2022
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ABBV-916 in Alzheimer's disease (AD), sponsored by AbbVie Inc.. Started Aug 2022; status: completed.
02
Drugs
ABBV-916
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05291234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05291234.